Nexpoint Asset Management’s Biotech Acquisition Company Class A Ordinary Shares BIOT Stock Holding History

Nexpoint Asset Management’s Portfolio BIOT Stock Details BIOT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-34,781	Closed	-$343K	–	172
2022 Q1	$343K	Hold	34,781	–	–	0.04%	113
2021 Q4	$342K	Hold	34,781	–	–	0.05%	156
2021 Q3	$339K	Buy	34,781 +10,981	+46%	+$106K	0.06%	130
2021 Q2	$230K	Buy	+23,800	New	+$231K	0.05%	140

Other funds holding BIOT

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CCP

Corbin Capital Partners New York $61.3M AUM 53.03% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

SCM

Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return

Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return

RiverPark Advisors New York $219M AUM 14.89% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Nexpoint Asset Management's BIOT Position: Q2 2022 in Review

Nexpoint Asset Management sold out of Biotech Acquisition Company Class A Ordinary Shares (BIOT) in Q2 2022, closing a stake of 34,781 shares — an estimated $343K sold.

Nexpoint Asset Management first reported a position in BIOT in Q2 2021 and held it in 4 quarters. The position peaked at $343K in Q1 2022. 67 funds tracked by Wall St. Rank hold BIOT as of Q2 2022.

Nexpoint Asset Management reported no remaining Biotech Acquisition Company Class A Ordinary Shares position as of Q2 2022 after selling out during the quarter.
Nexpoint Asset Management sold 34,781 Biotech Acquisition Company Class A Ordinary Shares shares in Q2 2022, an estimated $343K.
Nexpoint Asset Management first reported a position in Biotech Acquisition Company Class A Ordinary Shares in Q2 2021 and held it in 4 quarters.
Nexpoint Asset Management's Biotech Acquisition Company Class A Ordinary Shares position peaked at $343K in Q1 2022.
67 funds tracked by Wall St. Rank held Biotech Acquisition Company Class A Ordinary Shares as of Q2 2022.

Based on Nexpoint Asset Management's 13F filing for Q2 2022, filed 15 Aug 2022.